Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A1 | P68400 | 8/20 | 0.38 |
| ▸ | CSNK2A2 | P19784 | 5/20 | 0.38 |
| ▸ | CSNK2B | P67870 | 4/20 | 0.38 |
| ▸ | MEN1 | O00255 | 4/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | NPY1R | P25929 | 1/20 | 0.36 |
| ▸ | NPY2R | P49146 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3835600 | 1.00 | CSNK2A1 (0.38) | CSNK2A1CSNK2A2CSNK2BMEN1KMT2A | |
| SCHEMBL5147750 | 0.87 | RAB9A (0.37) | CSNK2A1CSNK2A2CSNK2BMEN1KMT2A | |
| SCHEMBL5264737 | 0.82 | TRPV1 (0.37) | CSNK2A1CSNK2A2CSNK2BMEN1KMT2A | |
| SCHEMBL5149503 | 0.82 | TRPV1 (0.37) | CSNK2A1CSNK2A2CSNK2BMEN1KMT2A | |
| SCHEMBL5149330 | 0.80 | PTGER4 (0.35) | CSNK2A2CSNK2BMEN1KMT2AMAPT | |
| SCHEMBL2980724 | 0.76 | MEN1 (0.42) | MEN1KMT2ANPSR1MAPTKDM4E | |
| SCHEMBL5262210 | 0.76 | MEN1 (0.42) | MEN1KMT2ANPSR1MAPTKDM4E | |
| SCHEMBL5259518 | 0.76 | MAPT (0.40) | CSNK2A1MEN1KMT2ANPSR1MAPT | |
| SCHEMBL2980731 | 0.75 | MEN1 (0.43) | CSNK2A1CSNK2A2CSNK2BMEN1KMT2A | |
| SCHEMBL27607194 | 0.75 | SYK (0.45) | CSNK2A1CSNK2A2CSNK2BMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7786177-B2 | Phenylalanine enamide derivatives | UCB PHARMA S.A. (BE) | 2010-08-31 | — | — | US | disclosed |
| US-7645770-B2 | Phenylalanine enamide derivatives | UCB PHARMA S.A. (BE) | 2010-01-12 | — | — | US | disclosed |
| US-20090186914-A1 | Phenylalanine Enamide Derivatives | UCB PHARMA, S.A. (BE) | 2009-07-23 | — | — | US | disclosed |
| US-20090105291-A1 | Phenylalanine Enamide Derivatives | RIGEL PHARMACEUTICALS, INC. (US) | 2009-04-23 | — | — | US | disclosed |
| US-7501437-B2 | Phenylalanine enamide derivatives | UCB PHARMA, S.A. (BE) | 2009-03-10 | — | — | US | disclosed |
| US-20070167483-A1 | 2-[(2-Isopropylsulfanyl-3-oxo-spiro[3.5]non-1-en-1-yl)amino]-3-[4-([2,7]naphthyridin-1-ylamino)phenyl]propanoic acid; compounds can inhibit the binding of integrins to their ligands and are of use in the prophylaxis and treatment of immuno or inflammatory disorders | UCB PHARMA S.A. (BE) | 2007-07-19 | — | — | US | disclosed |
| EP-1780201-A2 | PHENYLALANINE ENAMIDE DERIVATIVES POSSESSING A CYCLOBUTENE GROUP, FOR USE AS INTEGRIN INHIBITORS | Celltech R&D Limited (GB) | 2007-05-02 | — | — | EP | disclosed |
| US-7122556-B2 | Phenylalanine enamide derivatives | CELLTECH R&D LIMITED (GB) | 2006-10-17 | — | — | US | disclosed |
| US-6878718-B2 | Phenylalanine enamide derivatives | CELLTECH R&D LIMITED (GB) | 2005-04-12 | — | — | US | disclosed |
| US-20050038084-A1 | Phenylalanine enamide derivatives | CELLTECH R&D LIMITED | 2005-02-17 | — | — | US | disclosed |
| US-20020169336-A1 | Phenylalanine enamide derivatives | UCB PHARMA S.A. (BE) | 2002-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105291-A1 | Phenylalanine Enamide Derivatives | PAH, HRH3, PRLHR | CSNK2A1 374/4885CSNK2A2 363/4885CSNK2B 286/4885 |
| US-20050038084-A1 | Phenylalanine enamide derivatives | PAH, ARRB1, ACVR2B | CSNK2A1 528/4885CSNK2A2 506/4885CSNK2B 347/4885 |
| US-20020169336-A1 | Phenylalanine enamide derivatives | CCR1, AHR, PAH | CSNK2A1 522/4885CSNK2A2 467/4885CSNK2B 426/4885 |
| US-20070167483-A1 | 2-[(2-Isopropylsulfanyl-3-oxo-spiro[3.5]non-1-en-1-yl)amino]-3-[4-([2,7]naphthyridin-1-ylamino)phenyl]propanoic acid; compounds can inhibit the binding of integrins to their ligands and are of use in the prophylaxis and treatment of immuno or inflammatory disorders | ITGB2, VCAM1, ITGB1 | CSNK2A1 568/4885CSNK2A2 617/4885CSNK2B 545/4885 |
| US-20090186914-A1 | Phenylalanine Enamide Derivatives | PAH, HRH3, PRLHR | CSNK2A1 374/4885CSNK2A2 363/4885CSNK2B 286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.